IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v122y2018i2p198-203.html
   My bibliography  Save this article

Consequences of restricted STI testing for young heterosexuals in the Netherlands on test costs and QALY losses

Author

Listed:
  • Suijkerbuijk, Anita W.M.
  • Over, Eelco A.B.
  • van Aar, Fleur
  • Götz, Hannelore M.
  • van Benthem, Birgit H.B.
  • Lugnér, Anna K.

Abstract

Due to rising costs caused by increasing demand for sexually transmitted infection (STI) care, the Dutch government changed the funding of STI clinics. In 2015, a more restrictive testing policy was introduced with syphilis and HIV tests only on indication for younger, heterosexual clients. We evaluated intended savings and missed syphilis and/or HIV infections and explored efficiency of possible test policies.

Suggested Citation

  • Suijkerbuijk, Anita W.M. & Over, Eelco A.B. & van Aar, Fleur & Götz, Hannelore M. & van Benthem, Birgit H.B. & Lugnér, Anna K., 2018. "Consequences of restricted STI testing for young heterosexuals in the Netherlands on test costs and QALY losses," Health Policy, Elsevier, vol. 122(2), pages 198-203.
    • Handle: RePEc:eee:hepoli:v:122:y:2018:i:2:p:198-203
    DOI: 10.1016/j.healthpol.2017.12.001
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168851017303408
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.healthpol.2017.12.001?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Bernie J. O'Brien & Kirsten Gertsen & Andrew R. Willan & A. Faulkner, 2002. "Is there a kink in consumers' threshold value for cost‐effectiveness in health care?," Health Economics, John Wiley & Sons, Ltd., vol. 11(2), pages 175-180, March.
    2. Feng Lin & Arielle Lasry & Stephanie L Sansom & Richard J Wolitski, 2013. "Estimating the Impact of State Budget Cuts and Redirection of Prevention Resources on the HIV Epidemic in 59 California Local Health Departments," PLOS ONE, Public Library of Science, vol. 8(3), pages 1-10, March.
    3. Rechel, Boika & Suhrcke, Marc & Tsolova, Svetla & Suk, Jonathan E. & Desai, Monica & McKee, Martin & Stuckler, David & Abubakar, Ibrahim & Hunter, Paul & Senek, Michaela & Semenza, Jan C., 2011. "Economic crisis and communicable disease control in Europe: A scoping study among national experts," Health Policy, Elsevier, vol. 103(2), pages 168-175.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Javad Moradpour & Aidan Hollis, 2021. "The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 1139-1151, May.
    2. Jack Dowie, 2004. "Why cost‐effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 453-459, May.
    3. A. Gafni & S. D. Walter & S. Birch & P. Sendi, 2008. "An opportunity cost approach to sample size calculation in cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 17(1), pages 99-107, January.
    4. Powdthavee, Nattavudh & van den Berg, Bernard, 2011. "Putting different price tags on the same health condition: Re-evaluating the well-being valuation approach," Journal of Health Economics, Elsevier, vol. 30(5), pages 1032-1043.
    5. Jesús Martín-Fernández & Gloria Ariza-Cardiel & Luz Mª Peña-Longobardo & Elena Polentinos-Castro & Juan Oliva-Moreno & Ana Isabel Gil-Lacruz & Héctor Medina-Palomino & Isabel del Cura-González, 2017. "“Gaining or losing”: The importance of the perspective in primary care health services valuation," PLOS ONE, Public Library of Science, vol. 12(12), pages 1-14, December.
    6. Beatriz Rodríguez-Sánchez & Luz María Peña-Longobardo & Juan Oliva-Moreno, 2022. "The employment situation of people living with HIV: a closer look at the effects of the 2008 economic crisis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(3), pages 485-497, April.
    7. Whynes, David K. & Sach, Tracey H., 2007. "WTP and WTA: Do people think differently?," Social Science & Medicine, Elsevier, vol. 65(5), pages 946-957, September.
    8. Christian R. C. Kouakou & Thomas G. Poder, 2022. "Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(2), pages 277-299, March.
    9. Rechel, Bernd, 2019. "Funding for public health in Europe in decline?," Health Policy, Elsevier, vol. 123(1), pages 21-26.
    10. Pedram Sendi, 2021. "Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve," PharmacoEconomics, Springer, vol. 39(2), pages 161-169, February.
    11. Don Husereau & Brian Feagan & Carl Selya-Hammer, 2018. "Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching," Applied Health Economics and Health Policy, Springer, vol. 16(3), pages 279-288, June.
    12. Gafni, Amiram & Birch, Stephen, 2006. "Incremental cost-effectiveness ratios (ICERs): The silence of the lambda," Social Science & Medicine, Elsevier, vol. 62(9), pages 2091-2100, May.
    13. Neil Hawkins & David A. Scott, 2011. "Reimbursement and value‐based pricing: stratified cost‐effectiveness analysis may not be the last word," Health Economics, John Wiley & Sons, Ltd., vol. 20(6), pages 688-698, June.
    14. Simon Eckermann, 2015. "Kinky Thresholds Revisited: Opportunity Costs Differ in the NE and SW Quadrants," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 7-13, February.
    15. Nancy Devlin & David Parkin, 2004. "Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 437-452, May.
    16. Felix Achana & Stavros Petrou & Kamran Khan & Amadou Gaye & Neena Modi, 2018. "A methodological framework for assessing agreement between cost-effectiveness outcomes estimated using alternative sources of data on treatment costs and effects for trial-based economic evaluations," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 75-86, January.
    17. Isabel Llavero-Molino & María Teresa Sánchez-Ocón & María Ángeles Pérez-Morente & Beatriz Espadafor-López & Adelina Martín-Salvador & Encarnación Martínez-García & César Hueso-Montoro, 2019. "Sexually Transmitted Infections and Associated Factors in Homosexuals and Bisexuals in Granada (Spain) during the Period 2000–2015," IJERPH, MDPI, vol. 16(16), pages 1-12, August.
    18. Steven Alberts & Tiffany Yu & Robert Behrens & Lindsay Renfro & Geetika Srivastava & Gamini Soori & Shaker Dakhil & Rex Mowat & John Kuebler & George Kim & Miroslaw Mazurczak & John Hornberger, 2014. "Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer," PharmacoEconomics, Springer, vol. 32(12), pages 1231-1243, December.
    19. Hao Dong & Zhenghui Li & Pierre Failler, 2020. "The Impact of Business Cycle on Health Financing: Subsidized, Voluntary and Out-of-Pocket Health Spending," IJERPH, MDPI, vol. 17(6), pages 1-24, March.
    20. Adam Zydroń & Krzysztof Szoszkiewicz & Cyprian Chwiałkowski, 2021. "Valuing Protected Areas: Socioeconomic Determinants of the Willingness to Pay for the National Park," Sustainability, MDPI, vol. 13(2), pages 1-11, January.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:122:y:2018:i:2:p:198-203. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.